(Updates the headline and first paragraph with latest company filing.)
Novavax (NVAX) said Wednesday it is still awaiting a decision from the US Food and Drug Administration on its biologics license application for its Covid vaccine.
The vaccine approval is in limbo after the FDA missed a deadline, but a decision could be any day, The Wall Street Journal reported earlier.
The FDA previously allowed emergency use of Novavax's vaccine and the agency's decision would have determined whether to grant the vaccine a full approval, the report said, citing sources.
FDA did not immediately respond to requests for comment from MT Newswires.
NVAX shares were up 3% in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。